Glioblastoma Multiforme Treatment Market Size Report, 2034

Glioblastoma Multiforme Treatment Market - By Treatment Type, By Gender, By End Use - Global Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional

2.2.2&nbsp;&nbsp;&nbsp; Treatment type

2.2.3&nbsp;&nbsp;&nbsp; Gender

2.2.4&nbsp;&nbsp;&nbsp; End use

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing incidence of glioblastoma

3.2.1.2&nbsp;&nbsp;&nbsp; Growing advancements in diagnostic and treatment modalities

3.2.1.3&nbsp;&nbsp;&nbsp; Rising awareness and early diagnosis of disease

3.2.1.4&nbsp;&nbsp;&nbsp; Growing Investments in oncology research and development

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High recurrence rate of glioblastoma even after treatment

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of treatment

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Clinical trials for novel therapies

3.2.3.2&nbsp;&nbsp;&nbsp; Collaborations and strategic alliances accelerate innovation

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Technology landcsape

3.5&nbsp;&nbsp;&nbsp; Pipeline analysis

3.6&nbsp;&nbsp;&nbsp; Future market trends

3.7&nbsp;&nbsp;&nbsp; Regulatory landscape

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Key developments

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Non-pharmacological treatment

5.2.1&nbsp;&nbsp;&nbsp; Surgery

5.2.2&nbsp;&nbsp;&nbsp; Radiation therapy

5.2.3&nbsp;&nbsp;&nbsp; Tumor treating field therapy

5.3&nbsp;&nbsp;&nbsp; Pharmacological treatment

5.3.1&nbsp;&nbsp;&nbsp; By type

5.3.1.1&nbsp;&nbsp;&nbsp; Chemotherapy

5.3.1.2&nbsp;&nbsp;&nbsp; Targeted therapy

5.3.2&nbsp;&nbsp;&nbsp; By durg class

5.3.2.1&nbsp;&nbsp;&nbsp; Temozolomide

5.3.2.2&nbsp;&nbsp;&nbsp; Bevacizumab

5.3.2.3&nbsp;&nbsp;&nbsp; Lomustine

5.3.2.4&nbsp;&nbsp;&nbsp; Carmustine wafers

5.3.3&nbsp;&nbsp;&nbsp; By dosage form

5.3.3.1&nbsp;&nbsp;&nbsp; Oral

5.3.3.2&nbsp;&nbsp;&nbsp; Parenteral

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Male

6.3&nbsp;&nbsp;&nbsp; Female

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Cancer treatment centers

7.4&nbsp;&nbsp;&nbsp; Ambulatory surgical centers

7.5&nbsp;&nbsp;&nbsp; Other end use

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Amgen

9.2&nbsp;&nbsp;&nbsp; Amneal Pharmaceuticals

9.3&nbsp;&nbsp;&nbsp; Azurity Pharmaceuticals

9.4&nbsp;&nbsp;&nbsp; Curtana Pharmaceuticals

9.5&nbsp;&nbsp;&nbsp; Denovo Biopharma

9.6&nbsp;&nbsp;&nbsp; F. Hoffmann La Roche (Genentech)

9.7&nbsp;&nbsp;&nbsp; Karyopharm Therapeutics

9.8&nbsp;&nbsp;&nbsp; Merck

9.9&nbsp;&nbsp;&nbsp; NextSource Pharma

9.10&nbsp;&nbsp;&nbsp; Novocure

9.11&nbsp;&nbsp;&nbsp; Pfizer

9.12&nbsp;&nbsp;&nbsp; Sumitomo Dainippon Pharma

9.13&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries

9.14&nbsp;&nbsp;&nbsp; Teva Pharmaceuticals 
&nbsp;

Glioblastoma Multiforme Treatment Market

Get a free sample of this report